MM-MSCs express high levels of HAPLN1, generally cleaved by the matrix metalloproteinase 2 to release a small fragment, which is able to enhance NF-κB activation in MM cells, by reducing PI-induced apoptotic cell death. Here, HAPLN1 is linked to Miyoshi myopathy.